Abstract:Introduction Rapid and accurate point-of-care (POC) tuberculosis (TB) diagnostics are a key priority to close the TB diagnostic gap of 3.1 million people without a diagnosis. Leveraging the recent surge in COVID-19 diagnostic innovation, we explored the potential adaptation of commercially available SARS-CoV-2 tests for TB diagnosis, aligning with World Health Organization (WHO) target product profiles (TPPs). Methods A scoping review was conducted following PRISMA-ScR guidelines to systematically map commercially available POC molecular and antigen SARS-CoV-2 diagnostic tests potentially meeting the TPPs for TB diagnostic tests for peripheral settings. Data were gathered from PubMed/MEDLINE, bioRxiv, and medRxiv, along with publicly accessible in vitro diagnostic test databases, and developer websites, up to November 23, 2022. Data on developer and test attributes, operational characteristics, pricing, and clinical performance were charted using standardized data extraction forms. Each identified test was evaluated using a standardized scorecard. A narrative synthesis of the charted data is presented. Results Our database search yielded 2,003 studies, from which 408 were considered eligible. Among these, we identified 58 commercialized diagnostic devices, including 17 near-POC antigen tests, one POC molecular test, 29 near-POC molecular tests, and 11 low-complexity molecular tests. We summarized the detailed characteristics, regulatory status, and clinical performance data of these tests. The LumiraDx (Roche, Switzerland) emerged as the highest-scoring near-POC antigen platform, while Visby (Visby, USA) was the highest-performing near-POC molecular platform. The Lucira Check-It (Pfizer, USA) was noted as the sole POC molecular test. The IdyllaTM (Biocartis, Switzerland) was identified as the leading low-complexity molecular test. Discussion We highlight a diverse landscape of commercially available diagnostic tests suitable for potential adaptation to TB POC testing. This work aims to bolster global TB initiatives by fostering stakeholder collaboration, leveraging COVID-19 diagnostic technologies for TB diagnosis, and uncovering new commercial avenues to tackle longstanding challenges in TB diagnosis.

The changing landscape of diagnostic services for tuberculosis

Innovative laboratory methods for improved tuberculosis diagnosis and drug-susceptibility testing

[Diagnosis of tuberculosis in developing countries: new perspectives]

New developments in tuberculosis diagnosis and treatment

Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines

New tools and emerging technologies for the diagnosis of tuberculosis: Part II. Active tuberculosis and drug resistance

Reversing the tide of tuberculosis in India: complementing microscopy with line probe assays

Rapid Molecular Assays for the Diagnosis of Drug-Resistant Tuberculosis

Advances in the molecular diagnosis of tuberculosis: From probes to genomes

Improving the diagnosis of tuberculosis: old and new laboratory tools

Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination

What is New in the Diagnosis of Childhood Tuberculosis?

The laboratory diagnostics of tuberculosis

Blazing the trail for innovative tuberculosis diagnostics

Advances in the detection and diagnosis of tuberculosis using optical-based devices

The future in diagnostic tools for TB outbreaks: A review of the approaches with focus on LAMP and RPA diagnostics tests

Innovative COVID-19 Point-of-Care Diagnostics Suitable for Tuberculosis Diagnosis: A Scoping Review

Development, roll-out and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt and how can we do better?

Diagnosis of extra pulmonary tuberculosis: An update on novel diagnostic approaches

Progression in Point-of-Care Testing for Tuberculosis

Progress on Diagnosis and Treatment of Latent Tuberculosis Infection